Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Wilms Tumor 8Rhabdoid Tumor 7Osteosarcoma 7Neuroblastoma 7Lymphoma, Non-Hodgkin 7Hepatoblastoma 7Sarcoma 6Rhabdomyosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Histiocytosis, Langerhans-Cell 6Glioma 6Ependymoma 6Central Nervous System Neoplasms 5Sarcoma, Ewing 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Lung Neoplasms 3Ovarian Neoplasms 2Neuroendocrine Tumors 2Nasopharyngeal Carcinoma 2Immunoglobulin Light-chain Amyloidosis 2Endometrial Neoplasms 2Desmoid Tumors 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Xanthogranuloma, Juvenile 1Thyroid Cancer, Papillary 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Sarcoma, Synovial 1

Interventions

Fulvestrant 63Letrozole 53Paclitaxel 49Trastuzumab 41pembrolizumab 40ribociclib 37Specimen Handling 37palbociclib 36Capecitabine 34Carboplatin 33Anastrozole 33Tamoxifen 32exemestane 29pertuzumab 28abemaciclib 28Magnetic Resonance Spectroscopy 26Cyclophosphamide 26trastuzumab deruxtecan 24Surveys and Questionnaires 21Radiotherapy 18Biopsy 18olaparib 17Standard of Care 16Docetaxel 16Blood Specimen Collection 16Taxes 14Mastectomy, Segmental 14eribulin 13elacestrant 13130-nm albumin-bound paclitaxel 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Phantoms, Imaging × 90 days × Clear all
NCT02849496 2026-05-22

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
81 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡